The integrity of research into Medtronic's (NYSE:MDT) bone-growth protein Infuse, which is used in spine surgery, has been called into question by a Senate Finance Committee report that says the company was "heavily involved in drafting, editing and shaping the content of medical journal articles" about the product. Medtronics also paid $210M for unrelated work to the doctors who wrote the articles.